Shawn Cross - Dec 27, 2023 Form 4 Insider Report for Applied Molecular Transport Inc. (AMTI)

Role
CEO & Chair of the Board, Director
Signature
/s/ Brandon Hants Attorney-in-Fact for Shawn Cross
Stock symbol
AMTI
Transactions as of
Dec 27, 2023
Transactions value $
$0
Form type
4
Date filed
12/28/2023, 05:29 PM
Previous filing
Nov 24, 2023
Next filing
Jun 5, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AMTI Common Stock Disposed to Issuer -545K -100% 0 Dec 27, 2023 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AMTI Stock Option (Right to Buy) Disposed to Issuer $0 -300K -100% $0.00* 0 Dec 27, 2023 Common Stock 300K $4.61 Direct F3
transaction AMTI Stock Option (Right to Buy) Disposed to Issuer $0 -63K -100% $0.00* 0 Dec 27, 2023 Common Stock 63K $56.61 Direct F3
transaction AMTI Stock Option (Right to Buy) Disposed to Issuer $0 -94.5K -100% $0.00* 0 Dec 27, 2023 Common Stock 94.5K $8.29 Direct F3
transaction AMTI Stock Option (Right to Buy) Disposed to Issuer $0 -84K -100% $0.00* 0 Dec 27, 2023 Common Stock 84K $3.99 Direct F3
transaction AMTI Stock Option (Right to Buy) Disposed to Issuer $0 -668K -100% $0.00* 0 Dec 27, 2023 Common Stock 668K $0.39 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Shawn Cross is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 Pursuant to the Agreement and Plan of Merger dated as of September 21, 2023 (the "Merger Agreement"), by and among Cyclo Therapeutics, Inc. ("Cyclo"), Cameo Merger Sub, Inc. and the Issuer, each share of Issuer's Common Stock was converted into 0.1331 of a share of Cyclo Common Stock (the "Transaction Consideration").
F2 Upon consummation of the Merger, the Reporting Person received Transaction Consideration of 72,606 shares of Cyclo common stock.
F3 Pursuant to the Merger Agreement, at the effective time of the merger, each outstanding option with an exercise price of $0.40 or more was cancelled effective as of the closing.
F4 Pursuant to the Merger Agreement, this option was exchanged for an option covering 88,910 shares of Cyclo Common Stock.